Payment overview · 2025
General Payments
$501.84
19 reported records · 11 companies
Healthcare provider profile · identity verified
Vijay Korimilli, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SUGAR LAND, TX · NPI 1801091384
Verified facts
What the public records show
CMS Open Payments records show Vijay Korimilli, MD received $501.84 in general payments during 2025 across 19 reported records.
Ceribell, Inc. accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ceribell, Inc. | Unresolved — no canonical attribution shown | $127.20 | 25.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $94.01 | 18.7% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $83.17 | 16.6% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.64 | 6.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.47 | 6.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $30.36 | 6.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $28.37 | 5.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.04 | 4.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.27 | 3.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$17.31 | 3.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.00 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $501.84 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| POCKET EEG DEVICE Normalized: pocket eeg device |
Device | Ceribell, Inc. | $127.20 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $94.01 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $58.68 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.63 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.64 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.47 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.47 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $30.36 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $28.37 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.62 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.04 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 615 | 154 |
| Eliquis | Apixaban | 437 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 396 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 336 | 91 |
| Donepezil Hcl | Donepezil Hcl | 306 | 58 |
| Furosemide | Furosemide | 295 | 103 |
| Quetiapine Fumarate | Quetiapine Fumarate | 288 | 75 |
| Gabapentin | Gabapentin | 280 | 84 |
| Sertraline Hcl | Sertraline Hcl | 259 | 50 |
| Trazodone Hcl | Trazodone Hcl | 247 | 58 |
| Omeprazole | Omeprazole | 221 | 66 |
| Memantine Hcl | Memantine Hcl | 215 | 42 |
| Losartan Potassium | Losartan Potassium | 208 | 50 |
| Metformin Hcl | Metformin Hcl | 200 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 198 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 191 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 190 | 57 |
| Mirtazapine | Mirtazapine | 187 | 43 |
| Lisinopril | Lisinopril | 170 | 46 |
| Hydralazine Hcl | Hydralazine Hcl | 161 | 45 |
| Ondansetron Hcl | Ondansetron Hcl | 153 | 142 |
| Potassium Chloride | Potassium Chloride | 150 | 48 |
| Carvedilol | Carvedilol | 141 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 139 | 34 |
| Famotidine | Famotidine | 134 | 42 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 124 | 86 |
| Escitalopram Oxalate | Escitalopram Oxalate | 117 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 115 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 88 | 70 |
| Levetiracetam | Levetiracetam | 87 | 21 |
| Allopurinol | Allopurinol | 86 | 13 |
| Lorazepam | Lorazepam | 85 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 85 | 32 |
| Amiodarone Hcl | Amiodarone Hcl | 81 | 22 |
| Finasteride | Finasteride | 81 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 22 |
| Xarelto | Rivaroxaban | 76 | suppressed |
| Baclofen | Baclofen | 74 | 18 |
| Enulose | Lactulose | 69 | 26 |
| Buspirone Hcl | Buspirone Hcl | 68 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 61 | 19 |
| Divalproex Sodium | Divalproex Sodium | 61 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 20 |
| Nifedipine Er | Nifedipine | 58 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 15 |
| Glipizide | Glipizide | 50 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 48 | 30 |
| Jardiance | Empagliflozin | 48 | suppressed |
| Latanoprost | Latanoprost | 47 | 18 |
| Olanzapine | Olanzapine | 47 | suppressed |
| Simvastatin | Simvastatin | 47 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 39 |
| Atenolol | Atenolol | 46 | suppressed |
| Prednisone | Prednisone | 46 | 17 |
| Sucralfate | Sucralfate | 46 | 12 |
| Midodrine Hcl | Midodrine Hcl | 45 | 24 |
| Nystatin | Nystatin | 45 | 34 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | suppressed |
| Gemtesa | Vibegron | 44 | suppressed |
| Methocarbamol | Methocarbamol | 42 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 35 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 26 |
| Digoxin | Digoxin | 37 | suppressed |
| Levofloxacin | Levofloxacin | 37 | 29 |
| Meropenem | Meropenem | 37 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Nystop | Nystatin | 35 | 19 |
| Montelukast Sodium | Montelukast Sodium | 34 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | 17 |
| Meloxicam | Meloxicam | 32 | suppressed |
| Scopolamine | Scopolamine | 32 | suppressed |
| Vascepa | Icosapent Ethyl | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Risperidone | Risperidone | 31 | suppressed |
| Ezetimibe | Ezetimibe | 30 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 27 |
| Bumetanide | Bumetanide | 29 | 13 |
| Cefdinir | Cefdinir | 29 | 25 |
| Fluconazole | Fluconazole | 29 | 23 |
| Rivastigmine | Rivastigmine Tartrate | 29 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | 20 |
| Methylprednisolone | Methylprednisolone | 28 | 23 |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Amantadine | Amantadine Hcl | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 11 |
| Glimepiride | Glimepiride | 26 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 26 | 11 |
| Spironolactone | Spironolactone | 26 | suppressed |
| Naproxen | Naproxen | 25 | 17 |
| Mupirocin | Mupirocin | 24 | 14 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 23 | suppressed |
| Ertapenem | Ertapenem Sodium | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Rivastigmine | Rivastigmine | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 11 |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Movantik | Naloxegol Oxalate | 16 | suppressed |
| Multaq | Dronedarone Hcl | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Nateglinide | Nateglinide | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Admelog Solostar | Insulin Lispro | 14 | suppressed |
| Budesonide | Budesonide | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Lactulose | Lactulose | 14 | 13 |
| Methimazole | Methimazole | 14 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | 12 |
| Haloperidol | Haloperidol | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $501.84 · 19 records | Ceribell, Inc. | CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, GEMTESA, INTELLIS ADAPTIVESTIM, OTEZLA, Ozempic, POCKET EEG DEVICE, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error